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Three of eleven monoclon~ antibodies (~bs) to human placental alkaline phosphatase (PLAP) were 
shown to block cleavage by trypsin at the only proteo~~i~ally sensitive site on the native mole&e. These 
results illustrate the potential importance of using mAbs to restrict proteolysis of proteins, in general, and 
serve as a novel means to identify the relative locations of antigenic determinants. 
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1, INTRODUCTION 
Since the establishment of the h~bridoma tech- 
nique as in [I J, the use of monoclonal antibodies 
(mAbs) as exquisite reagents in biochemistry has 
broadened dramatically. Usually the mAb binds to 
a conformation-dependent determinant at the sur- 
face of the antigen making the mAb useful for 
detection of the native antigen in tissues and 
biological fluids, and for its isolation by im- 
munoadsorption or immunoprecipitation. The 
mAbs are also usefui in studying structure and 
function relationships in proteins. Functions pro- 
perties of the antigen often can be bfocked by 
mAbs allowing the function to be localized to a 
particular region of the folded pol~eptide chain. 
cleaved by trypsin, reducing the molecular mass of 
the two identical subunits from 67 kDa each to 
other proteases including ch~otrypsin and pa- 
pain. Several research groups have reported the 
production of mAbs to PLAP [3-91. A total of 
eleven mAbs from two of these groups [4,7,9] are 
examined here for their ability to block trypsin 
cleavage of PLAP. 
2. MATERIALS AND METHODS 
The present investigation demonstrates that 
mAbs can be used to block specific proteolytic 
cleavage sites of an antigen. These results further 
add to the usefulness of mAbs as tools in 
biochemistry. 
Of the I1 mAbs to PLAP, 4 (Fll = IgC1, DlO = 
IgGi, H7 = IgGza, BlO = IgGza) were generated 
against purified PLAP (SS or FS type) f4,7] and 7 
(610 = IgGzi,, B2 = IgGzb, H5 = IgGr, ES = 
IgGza, F6 = IgGt,, C4 = IgGzb, A3 = IgGr) were 
generated against HeLa TCRC-1 cells [9], an 
adenocarcinoma cell line which synthesizes PLAP 
ectopically [lo]. 
Human placental alkaline phosphatase (PLAP) 
in its native form has been shown to be partially 
cleaved by trypsin, reducing the molecular weight 
2.2. PLAP prepffrat~on 
Abbreviation: mAb, monoc~on~ antibody; PLAP, 
placental alkaline phosphatase; SDS-PAGE, POSY- 
acrylamide gel eiectrophoresis in sodium dodecyl sulfate 
The enzyme was purified from an individual SS 
type human placenta which was homogenized, ex- 
tracted with butanol, and further processed to 
homogeneity as reported elsewhere { 111. In some 
experiments PLAP was radiolabelled with *251 us- 
ing chloramine T [ 121. 
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2.3. Trypsiin digestion 1 2 
Trypsin (TPCK-treated) was purchased from 
Sigma Chemical Co. (St. Louis, MO). PLAP 
(1 mg/ml) was digested with 2% trypsin in 
phosphate-buffered saline pH 8.3 at room 
temperature for 24 h. For several antibody block- 
ing experiments, an equal molar amount of mAb 
was incubated with PLAP for at least 1 h prior to 
addition of trypsin. In other experiments, the 
mAbs were tested for blocking of proteolysis using 
‘251-labeiled PLAP. In these experiments, mAb 
(lOpg), bovine serum albumin (lOO~g), and 12’1- 
PLAP (0.5 pug) were mixed prior to proteolytic 
digestion. 
2.4. SDS-PAGE 
SDS-PAGE in 10% slab gels was performed as 
in [13]. Standard markers used included bovine 
serum albumin (67 kDa), ovalbumin (45 kDa), 
trypsinogen (24 kDa), and cytochrome c (13 kDa). 
After Coomassie blue staining, the gels were dried 
and subjected to autoradiography using Kodak 
XAR-5 film. 
3. RESULTS 
In its native state, PLAP is cleaved at only one 
site by trypsin and the major fragment is not fur- 
ther degraded. As seen in fig. 1, the molecular mass 
of the two identical subunits is decreased by only 
10 kDa. The smaller fragment is probably further 
degraded after the initial cleavage since it does not 
appear in SDS-PAGE either by protein staining or 
autoradiography when “‘1-PLAP is used. 
Fig. 1. Effect of trypsin on the migration of radiolabelled 
PLAP in SDS-PAGE. Lane 1, native PLAP; lane 2, 
trypsin-digested PLAP. 
Trypsin also has only a limited effect on the 
mAbs as seen in fig.2 (lanes 2 and 7). It seems that 
only the heavy chain is cleaved, probably in the 
proteolytically-sensitive Fc region which is not in- 
volved in antibody binding. Trypsin does not in- 
fluence the binding between the mAb and PLAP as 
seen by the ability of E5 to completely protect 
PLAP from proteolytic attack (lane 3). In con- 
trast, H7 only partially blocks the effect of trypsin 
(lane 6). Note that ES and H7 are proteolyzed the 
same whether or not antigen is present, indicating 
that the combining sites of the mAbs which would 
probably protect the antigen are not attacked by 
trypsin. 
A total of eleven mAbs were examined for their 
Fig.2. Effects of trypsin on the molecular mass of mAb- 
free and mAb-bound PLAP shown by SDS-PAGE. 
Lane 1, E5; Iane 2, ES + trypsin; lane 3, ES-PLAP 
complex + trypsin; lane 4, PLAP + trypsin; lane 5, 
PLAP; lane 6, H?-PLAP complex + trypsin; lane 7, H7 
+ trypsin; lane 8, H7. 
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Fig.3. Autoradiography from SDS-PAGE of r2?- 
PLAP bound to eleven mAbs and then treated with 
trypsin. NS = nonspecific mouse IgG. 
ability to block trypsin cleavage of radiolabelled 
PLAP as seen in fig.3. The mAbs can be classified 
into three groups based on their effects on trypsin 
cleavage: completely blocking (F6, E5 and C4), 
partially blocking (A3 and H7), and not blocking 
(GlO, B2, H5, Fll, DlO and BlO). 
4. DISCUSSION 
Competition experiments assessing the binding 
of these eleven mAbs to PLAP indicate that F6, 
E5, and C4, which block trypsin cleavage, pro- 
bably bind to the same antigenic determinant on 
the molecule, a site distinct from any which would 
be occupied by the other eight mAbs [14]. These 
three mAbs do not bind at the cleavage site but in 
its vicinity. Indeed, all the mAbs except A3 bind to 
the 57 kDa fragment produced by trypsin cleavage 
of PLAP [2], making it unlikely that trypsin 
cleaves within the antigenic determinant. Thus, the 
effects of F6, E5, and C4 are probably due to steric 
hindrance by the antibody polypeptide chains pro- 
tecting the trypsin cleavage site. 
Identification of similar types of blocking mAbs 
on other proteins may be useful in studies of struc- 
ture and function relations. By protecting certain 
proteolytic cleavage sites, one can theoretically 
engineer a proteolytic digestion to yield more pur- 
posefully constructed peptide fragments. Further- 
more, the effects of proteolysis on the activation or 
deactivation of a protein in vivo may be monitored 
using mAbs which block proteolytic cleavage at a 
specific site. 
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